Anti-TGF-beta 1 therapy fails to slow progression of diabetic nephropathy

16 Dec 2014


A randomised control study found that, while anti-TGF-beta 1 therapy was safe and well-tolerated, it failed to slow disease progression in patients with advanced diabetic nephropathy. Clinical Endocrinology News

 


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story